ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.2275G>T (p.Gly759Ter)

dbSNP: rs63749854
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076448 SCV000107477 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Coding sequence variation introducing premature termination codon
Ambry Genetics RCV000223378 SCV000273589 pathogenic Hereditary cancer-predisposing syndrome 2023-03-03 criteria provided, single submitter clinical testing The p.G759* pathogenic mutation (also known as c.2275G>T), located in coding exon 14 of the MSH2 gene, results from a G to T substitution at nucleotide position 2275. This changes the amino acid from a glycine to a stop codon within coding exon 14. This variant has been identified in a proband(s) whose Lynch syndrome-associated tumor demonstrated loss of MSH2 expression by immunohistochemistry (Stormorken AT et al. J Clin Oncol. 2005 Jul 20;23(21):4705-12; Grindedal EM et al. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2460-7; Sjursen W et al. J Med Genet. 2010 Sep;47(9):579-85). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000798392 SCV000938008 pathogenic Hereditary nonpolyposis colorectal neoplasms 2022-10-08 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 90946). This premature translational stop signal has been observed in individual(s) with Lynch syndrome and prostrate cancer (PMID: 15342696, 16034045, 19723918, 27601186, 28514183). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gly759*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816).
Myriad Genetics, Inc. RCV003452903 SCV004187933 pathogenic Lynch syndrome 1 2023-08-08 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.